Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma
- PMID: 24957555
- PMCID: PMC4364276
- DOI: 10.3109/0284186X.2014.923934
Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma
Abstract
Background: This study describes time-trends on epidemiology, subtypes and histopathological entities of osteosarcoma (OS) in a nationwide and unselected cohort of OS patients in Norway between 1975 and 2009. Few nationwide studies are published, and we still have particularly limited knowledge regarding patients not included in clinical trials comprising about half of the OS population.
Method: Histologically verified skeletal OS for all subgroups were included, resulting in 473 eligible cases from a total of 702 evaluated patients. To ensure completeness, the present cohort was based on all cases reported to the Norwegian Cancer Registry, complemented with data from all Norwegian hospitals involved in sarcoma management. Survival analyses were performed with overall and sarcoma-specific survival as endpoints.
Results: Mean annual age-standard incidence amounted to about 3.8 per million in male and 2.8 per million in female with no clear time-trends. The male to female ratio was 1.4. Peak incidence was observed in the second decade for both genders. Conventional OS comprised 71.2% of all cases, while low grade OS represented 10.4% and telangiectatic OS only 1.3%. The most common primary site of OS was femur and tibia, respectively. The axial to appendicular ratio increased with the age. The overall 10-year survival did increase from about 30% during the late 1970s to around 50% 20 years later, with no subsequent improvement during the last two decades. Axial tumours, age above 40 years and overt metastatic disease at time of diagnosis were all negative prognostic factors.
Conclusion: No improvement in the overall survival for OS since the 1990s was documented. The survival rates are still poor for elderly people, patients with axial disease and in the primary metastatic setting. The average incidence rate of skeletal OS in Norway was in line with international figures.
Figures




Similar articles
-
Prognostic factors in high-grade pediatric osteosarcoma among children and young adults: Greek Nationwide Registry for Childhood Hematological Malignancies and Solid Tumors (NARECHEM-ST) data along with a systematic review and meta-analysis.Cancer Epidemiol. 2024 Jun;90:102551. doi: 10.1016/j.canep.2024.102551. Epub 2024 Mar 5. Cancer Epidemiol. 2024. PMID: 38447251
-
Descriptive epidemiology and outcomes of bone sarcomas in adolescent and young adult patients in Japan.BMC Musculoskelet Disord. 2018 Aug 18;19(1):297. doi: 10.1186/s12891-018-2217-1. BMC Musculoskelet Disord. 2018. PMID: 30121085 Free PMC article.
-
Italian cancer figures, report 2012: Cancer in children and adolescents.Epidemiol Prev. 2013 Jan-Feb;37(1 Suppl 1):1-225. Epidemiol Prev. 2013. PMID: 23585445 English, Italian.
-
Survival and prognostic factors at time of diagnosis in high-grade appendicular osteosarcoma: a 21 year single institution evaluation from east Denmark.Acta Oncol. 2018 Mar;57(3):420-425. doi: 10.1080/0284186X.2017.1351620. Epub 2017 Jul 25. Acta Oncol. 2018. PMID: 28741397
-
The epidemiology of osteosarcoma.Cancer Treat Res. 2009;152:3-13. doi: 10.1007/978-1-4419-0284-9_1. Cancer Treat Res. 2009. PMID: 20213383 Review.
Cited by
-
PARK2 inhibits osteosarcoma cell growth through the JAK2/STAT3/VEGF signaling pathway.Cell Death Dis. 2018 Mar 7;9(3):375. doi: 10.1038/s41419-018-0401-8. Cell Death Dis. 2018. PMID: 29515107 Free PMC article.
-
Advances in the management of osteosarcoma.F1000Res. 2016 Nov 25;5:2767. doi: 10.12688/f1000research.9465.1. eCollection 2016. F1000Res. 2016. PMID: 27990273 Free PMC article. Review.
-
Lnc-MAP6-1:3 knockdown inhibits osteosarcoma progression by modulating Bax/Bcl-2 and Wnt/β-catenin pathways.Int J Med Sci. 2020 Aug 21;17(15):2248-2256. doi: 10.7150/ijms.47405. eCollection 2020. Int J Med Sci. 2020. PMID: 32922188 Free PMC article.
-
IRF2 Destabilizes Oncogenic KPNA2 to Modulate the Development of Osteosarcoma.J Oncol. 2022 Sep 26;2022:9973519. doi: 10.1155/2022/9973519. eCollection 2022. J Oncol. 2022. PMID: 36199790 Free PMC article.
-
Multimodal treatment of craniofacial osteosarcoma with high-grade histology. A single-center experience over 35 years.Neurosurg Rev. 2017 Jul;40(3):449-460. doi: 10.1007/s10143-016-0802-z. Epub 2016 Nov 17. Neurosurg Rev. 2017. PMID: 27858303
References
-
- Unni KK, Inwards CY. Dahlinś bone tumors. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2010.
-
- Huvos AG. Bone tumors. Diagnosis, treatment and prognosis. 2nd ed. Philadelphia: W.B. Saunders; 1991.
-
- Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. WHO classification of tumours of soft tissue and bone. 4th ed. Lyon: International Agency for Research on Cancer; 2013.
-
- Bruland OS, Pihl A. On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer. 1997;33:1725–31. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical